Log in

NASDAQ:BIOS - BioScrip Stock Price, Forecast & News

-0.09 (-2.79 %)
(As of 12/8/2019 03:43 AM ET)
Today's Range
Now: $3.14
50-Day Range
MA: $3.41
52-Week Range
Now: $3.14
Volume1.40 million shs
Average Volume1.13 million shs
Market Capitalization$2.21 billion
P/E RatioN/A
Dividend YieldN/A
BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. Read More…

Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
Current SymbolNASDAQ:BIOS



Sales & Book Value

Annual Sales$708.90 million
Book Value($1.12) per share


Net Income$-51,690,000.00


Market Cap$2.21 billion
Next Earnings Date3/20/2020 (Estimated)

Receive BIOS News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOS and its competitors with MarketBeat's FREE daily newsletter.

BioScrip (NASDAQ:BIOS) Frequently Asked Questions

What is BioScrip's stock symbol?

BioScrip trades on the NASDAQ under the ticker symbol "BIOS."

How were BioScrip's earnings last quarter?

BioScrip Inc (NASDAQ:BIOS) posted its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.01) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.01). The company earned $615.88 million during the quarter, compared to analyst estimates of $522.20 million. BioScrip had a negative net margin of 7.19% and a negative return on equity of 42.56%. View BioScrip's Earnings History.

When is BioScrip's next earnings date?

BioScrip is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for BioScrip.

What price target have analysts set for BIOS?

4 brokers have issued 12 month price targets for BioScrip's shares. Their forecasts range from $2.51 to $4.25. On average, they anticipate BioScrip's share price to reach $3.69 in the next year. This suggests a possible upside of 17.7% from the stock's current price. View Analyst Price Targets for BioScrip.

What is the consensus analysts' recommendation for BioScrip?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioScrip in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioScrip.

What are Wall Street analysts saying about BioScrip stock?

Here are some recent quotes from research analysts about BioScrip stock:
  • 1. According to Zacks Investment Research, "Option Care Health exited the third quarter with in-line loss but revenues ahead of the consensus mark. We are optimistic about the company’s huge integration-related synergy benefits. Management stated that it is expected to generate revenues exceeding $2.6 billion. The merger is expected to result in an optimized capital structure and enhance the financial strength and flexibility. The company’s consistent growth in the Infusion services business and the diverse measures adopted by management to drive growth bolsters our confidence in the stock. In the last six months, Option Care Health has consistently outperformed the industry it belongs to. On the flip side, regulatory restrictions, reimbursement cuts and a competitive landscape are a few of the factors affecting revenue growth of the legacy BioScrip over the recent past." (11/18/2019)
  • 2. Barrington Research analysts commented, "We think they should have held one given that management is currently engaged in selling BIOS investors on the benefits of the pending Option Care transaction." (5/3/2019)

Has BioScrip been receiving favorable news coverage?

Headlines about BIOS stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. BioScrip earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an impact on the stock's share price in the next several days. View News Stories for BioScrip.

Who are some of BioScrip's key competitors?

What other stocks do shareholders of BioScrip own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioScrip investors own include Abraxas Petroleum (AXAS), Trevena (TRVN), Northern Oil & Gas (NOG), Acasti Pharma (ACST), Advanced Micro Devices (AMD), General Electric (GE), Seanergy Maritime (SHIP), Ford Motor (F), JPMorgan Chase & Co. (JPM) and Rite Aid (RAD).

Who are BioScrip's key executives?

BioScrip's management team includes the folowing people:
  • Mr. Daniel E. Greenleaf, CEO, Pres & Director (Age 54)
  • Mr. Stephen M. Deitsch, Sr. VP, CFO & Treasurer (Age 46)
  • Ms. Harriet Booker, Sr. VP & COO (Age 52)
  • Mr. John McMahon, VP, Controller & Chief Accounting Officer (Age 54)
  • Mr. Vito Ponzio Jr., Chief Admin. Officer & Sr. VP (Age 64)

Who are BioScrip's major shareholders?

BioScrip's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Gabelli Funds LLC (4.51%), GABELLI & Co INVESTMENT ADVISERS INC. (0.65%), Gamco Investors INC. ET AL (0.39%), Teton Advisors Inc. (0.12%), North Star Investment Management Corp. (0.02%) and SG Americas Securities LLC (0.02%). View Institutional Ownership Trends for BioScrip.

Which institutional investors are selling BioScrip stock?

BIOS stock was sold by a variety of institutional investors in the last quarter, including Gabelli Funds LLC, Teton Advisors Inc., Gamco Investors INC. ET AL and GABELLI & Co INVESTMENT ADVISERS INC.. View Insider Buying and Selling for BioScrip.

Which institutional investors are buying BioScrip stock?

BIOS stock was purchased by a variety of institutional investors in the last quarter, including North Star Investment Management Corp. and SG Americas Securities LLC. View Insider Buying and Selling for BioScrip.

How do I buy shares of BioScrip?

Shares of BIOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioScrip's stock price today?

One share of BIOS stock can currently be purchased for approximately $3.14.

How big of a company is BioScrip?

BioScrip has a market capitalization of $2.21 billion and generates $708.90 million in revenue each year. The company earns $-51,690,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis. BioScrip employs 2,043 workers across the globe.View Additional Information About BioScrip.

What is BioScrip's official website?

The official website for BioScrip is http://www.optioncarehealth.com/.

How can I contact BioScrip?

BioScrip's mailing address is 3000 Lakeside Dr. Suite 300N, Bannockburn IL, 60015. The company can be reached via phone at 312-940-2443 or via email at [email protected]

MarketBeat Community Rating for BioScrip (NASDAQ BIOS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  314 (Vote Outperform)
Underperform Votes:  275 (Vote Underperform)
Total Votes:  589
MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe BIOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Featured Article: Momentum Indicators

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel